Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new lens design is turning heads in pediatric eye care. A 24-month randomized trial found that spectacles with highly aspherical lenslets (HAL) reduced myopia progression by 71% and slowed eye elongation by 53% compared to standard single-vision lenses in children aged 6–12. The findings, published in JAMA Ophthalmology, suggest a promising new tool for managing childhood myopia.
A new type of spectacle lens could be a game-changer for the growing number of children with myopia. A 24-month randomized, double-masked clinical trial published in JAMA Ophthalmology found that highly aspherical lenslet (HAL) spectacles dramatically outperformed standard single-vision lenses (SVL) in slowing myopia progression among children aged 6 to 12.
The trial enrolled 159 children across 9 U.S. sites, with about 85% completing the full two-year follow-up. The HAL lenses were well-tolerated, with no serious lens-related adverse events, and visual acuity outcomes were comparable between groups.
By the Numbers:
Why it matters: Myopia is increasingly common in children and can lead to serious eye conditions later in life. HAL spectacles offer a non-invasive, accessible option for myopia management — though longer follow-up studies are still needed to confirm lasting benefits.
